| Revenue Growth | DAYBUE grew 39% to $140M; NUPLAZID grew 12% to $202M. |
|---|---|
| Mgmt Confidence | High conviction in 60mg dose for ADP despite Phase 2 miss. |
| Demand Visibility | Over 50% of US DAYBUE patients switched to sticks formulation. |
| Margin Trends | DAYBUE gross-to-net 23.2%; NUPLAZID gross-to-net 22.7% in Q3. |
| Op. Leverage | R&D expenses decreased to $76M from $88M year-over-year. |
| Pricing Power | Germany launch allows initial set price during reimbursement negotiations. |
| Vol vs Price | DAYBUE growth driven almost entirely by volume; NUPLAZID 11% volume growth. |
| Segment Growth | DAYBUE sticks driving restarts; NUPLAZID field force expansion doubling reach. |
| New Clients | NUPLAZID field force now engaging over 10,000 physicians. |
| Capex & Debt | Cash position of $976 million; no debt mentioned. |
| Regulatory | Received US PTO notice of allowance for patent extending protection to 2041. |
| Commentary | Strategic shift to 60mg dose and central raters for Phase 3. |
| New Launches | DAYBUE launched in Germany October 2026; sticks formulation driving growth. |
Growth
Total revenue $342M (up 22%); DAYBUE $140M (up 39%); NUPLAZID $202M (up 12%).
Outlook
Raised 2026 DAYBUE guidance to $505M-$520M; $700M DAYBUE and $1B NUPLAZID targets by 2028.
Risks
Phase 2 Radiant study narrowly missed statistical significance (p=0.0603) on the primary endpoint.
The company's earnings call, NASDAQ: ACAD, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Acadia Pharmaceuticals Inc: key numbers
- Share price
- $18.67Close, Nov 16
- Market cap
- $3.23B
- Shares outstanding
- 172.83MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Acadia Pharmaceuticals Inc
All →Acadia Pharmaceuticals Q3 2026 Results: Net Income $53.5M, Down 25.4% YoY
ACADIA Pharmaceuticals reported strong revenue growth driven by its commercial products, NUPLAZID and DAYBUE, alongside disciplined management of operating expenses. The company continues to invest in its late-stage clinical pipeline while showing significant progress toward sustained profitability.
- Key figure
- Net income $53.5M · -25.4% YoY
Acadia Pharmaceuticals Financial Results
Acadia Pharmaceuticals reported Q3 2026 total revenues of $342 million, a 22% increase year-over-year, driven by strong sales of DAYBUE and NUPLAZID. The company raised its 2026 net sales guidance for DAYBUE to $505–$520 million and highlighted upcoming Phase 2 readouts for its pipeline candidates in 2027.
- Term
- Q3 2026
“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID. In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build momentum following our recent launch of DAYBU in Germany. NUPLAZID also performed well, driven by underlying demand and the continued expansion of our commercial reach.”
Catherine Owen Adams, Chief Executive Officer of Acadia
Acadia Pharmaceuticals EVP, CFO Mark C. Schneyer Sells $69.3K of Stock
Mark C. Schneyer, EVP, CFO, sold 3,321 shares of Acadia Pharmaceuticals Inc at $20.88 a share, worth $69.3K in total on Oct 30, 2026. Shares held after the trade: 71,322 (-4.4%).
- Value
- $69.3K
- Shares
- 3,321
- Price
- $20.88
- Role
- EVP, CFO
- Holding change
- -4.4%
- Trade date
- Oct 30, 2026
Acadia Pharmaceuticals Leadership Change
Elizabeth H.Z. Thompson, Ph.D., has stepped down from her role as Executive Vice President and Head of Research and Development at Acadia Pharmaceuticals effective October 23, 2026. Dr. Thompson will transition to a consulting role through December 31, 2026, while the company continues its search for a permanent replacement.
- Term
- through Dec 2026
Acadia Pharmaceuticals Clinical Trial Data
Acadia Pharmaceuticals announced Phase 3 enabling topline results from the Phase 2 portion of its RADIANT trial evaluating remlifanserin for Alzheimer’s disease psychosis (ADP). While the 60 mg dose narrowly missed the primary endpoint (p=0.0603), it showed nominal significance on a key secondary endpoint and a favorable safety profile, leading the company to continue its Phase 3 program with the 60 mg dose.
- Earnings call
- Sep 24, 2026, 8:00 AM ET
Acadia Pharmaceuticals Court & Legal Update
The U.S. District Court for the Southern District of California has granted preliminary approval for a settlement of a stockholder derivative action against Acadia Pharmaceuticals and certain of its officers and directors. The settlement resolves claims related to the company's drug pimavanserin (NUPLAZID) and includes the implementation of corporate governance reforms and the payment of plaintiff attorney fees. A final settlement hearing is scheduled for January 13, 2027.
- Counterparty
- Kanner et al.